- Home
- JSPR vs VSTM Comparison
JSPR vs VSTM Comparison
Compare JSPR & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- VSTM
- Stock Information
- Founded
- JSPR 2018
- VSTM 2010
- Country
- JSPR United States
- VSTM United States
- Employees
- JSPR N/A
- VSTM N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- VSTM Health Care
- Exchange
- JSPR Nasdaq
- VSTM Nasdaq
- Market Cap
- JSPR 289.1M
- VSTM 239.9M
- IPO Year
- JSPR N/A
- VSTM 2012
- Fundamental
- Price
- JSPR $5.51
- VSTM $5.33
- Analyst Decision
- JSPR Strong Buy
- VSTM Strong Buy
- Analyst Count
- JSPR 11
- VSTM 8
- Target Price
- JSPR $67.75
- VSTM $12.43
- AVG Volume (30 Days)
- JSPR 874.5K
- VSTM 2.4M
- Earning Date
- JSPR 03-03-2025
- VSTM 03-13-2025
- Dividend Yield
- JSPR N/A
- VSTM N/A
- EPS Growth
- JSPR N/A
- VSTM N/A
- EPS
- JSPR N/A
- VSTM N/A
- Revenue
- JSPR N/A
- VSTM $10,000,000.00
- Revenue This Year
- JSPR N/A
- VSTM N/A
- Revenue Next Year
- JSPR N/A
- VSTM $69.02
- P/E Ratio
- JSPR N/A
- VSTM N/A
- Revenue Growth
- JSPR N/A
- VSTM N/A
- 52 Week Low
- JSPR $5.25
- VSTM $2.10
- 52 Week High
- JSPR $31.01
- VSTM $14.22
- Technical
- Relative Strength Index (RSI)
- JSPR 18.61
- VSTM 52.51
- Support Level
- JSPR $18.80
- VSTM $5.08
- Resistance Level
- JSPR $21.27
- VSTM $6.02
- Average True Range (ATR)
- JSPR 1.55
- VSTM 0.68
- MACD
- JSPR -1.43
- VSTM -0.06
- Stochastic Oscillator
- JSPR 1.47
- VSTM 49.21
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.